Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
Yuan Yuan, Jin Sun Lee, Susan E. Yost, et al.
The Oncologist (2020) Vol. 26, Iss. 3, pp. e382-e393
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
Xiaoxiao Wang, L. Collet, Mattia Rediti, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 953-953
Open Access | Times Cited: 34
Programmed cell death, redox imbalance, and cancer therapeutics
Xiaofeng Dai, Danjun Wang, Jianying Zhang
APOPTOSIS (2021) Vol. 26, Iss. 7-8, pp. 385-414
Closed Access | Times Cited: 49
Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas
Francesca Menghi, Kalyan Banda, Pooja Kumar, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 652
Open Access | Times Cited: 34
Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas
Zhichao Tian, Weitao Yao
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 28
Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast Cancers
Jeppe Thagaard, Elisabeth Specht Stovgaard, Line Grove Vognsen, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 3050-3050
Open Access | Times Cited: 34
Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis
Yue Chai, Yujie Chen, Di Zhang, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 2, pp. 323-323
Open Access | Times Cited: 26
Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives
Zhenjun Huang, Qing Peng, Luhui Mao, et al.
MedComm – Future Medicine (2025) Vol. 4, Iss. 1
Open Access
Innovative approaches in breast cancer therapy: repurposing nanocarriers for enhanced outcomes
Sana Naaz Siddiqui, Md. Faheem Haider, M.A. Rahman
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer
Elisabeth Specht Stovgaard, Iben Kümler, Kamille List-jensen, et al.
Applied immunohistochemistry & molecular morphology (2021) Vol. 30, Iss. 1, pp. 62-71
Closed Access | Times Cited: 29
Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis
Shiqi Li, Ying Zhang, Peigen Zhang, et al.
The Breast (2022) Vol. 66, pp. 97-109
Open Access | Times Cited: 21
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
Colt A. Egelston, Weihua Guo, Susan E. Yost, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 9, pp. 3013-3027
Open Access | Times Cited: 12
Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
Tara Hyder, Saveri Bhattacharya, Kristine Gade, et al.
Breast Cancer Targets and Therapy (2021) Vol. Volume 13, pp. 199-211
Open Access | Times Cited: 24
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
Myriam Kossaï, Nina Radosevic‐Robin, Frédérique Penault‐Llorca
ESMO Open (2021) Vol. 6, Iss. 5, pp. 100257-100257
Open Access | Times Cited: 24
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials
Lei Bian, Ping Yu, Jiahuai Wen, et al.
npj Breast Cancer (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 17
Therapeutic potential of human serum albumin nanoparticles encapsulated actinonin in murine model of lung adenocarcinoma
Priyanca Ahlawat, Kanika Phutela, Amanjit Bal, et al.
Drug Delivery (2022) Vol. 29, Iss. 1, pp. 2403-2413
Open Access | Times Cited: 11
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
Won‐Ji Ryu, Joohyuk Sohn
Pharmaceuticals (2021) Vol. 14, Iss. 10, pp. 1008-1008
Open Access | Times Cited: 15
Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
Olga Caramelo, Cristina Silva, Francisco Caramelo, et al.
Hereditary Cancer in Clinical Practice (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 10
Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress
Ernestina Marianna De Francesco, Francesca Cirillo, Veronica Vella, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 6, pp. 513-535
Closed Access | Times Cited: 8
A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer
Xiaomeng Jia, Kainan Wang, Lingzhi Xu, et al.
The Breast (2022) Vol. 66, pp. 31-39
Open Access | Times Cited: 8
Metastatic adult Wilms' tumor managed by chemotherapy, immunotherapy and target therapy: a case report
Qian Zhao, Qi Xiong, Qi Song
Future Science OA (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine
Muhammad Zubair Afzal, Linda T. Vahdat
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 719-719
Open Access | Times Cited: 1
Management of triple-negative breast cancer in the era of novel therapies
Rakesh Sharma, Ajay Gogia
Cancer Research Statistics and Treatment (2021) Vol. 4, Iss. 4, pp. 668-676
Open Access | Times Cited: 10
‘ADVANCE’ (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer
Rachel A. Freedman, Tianyu Li, Mina S. Sedrak, et al.
Journal of Geriatric Oncology (2022) Vol. 14, Iss. 1, pp. 101377-101377
Open Access | Times Cited: 7
Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis
Meng Xiu, Pin Zhang, Xiang Wang, et al.
International Journal of Cancer (2022) Vol. 151, Iss. 4, pp. 578-589
Open Access | Times Cited: 6
Multifunctional Graphene Oxide Nanodelivery Platform for Breast Cancer Treatment
Yousheng Mo, Wei Liu, Piaoxue Liu, et al.
International Journal of Nanomedicine (2022) Vol. Volume 17, pp. 6413-6425
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top